Stem Cell-Based Therapies for Inflammatory Bowel Disease
Hua-Min Zhang,Shuo Yuan,Huan Meng,Xiao-Ting Hou,Jiao Li,Jia-Chen Xue,You Li,Qi Wang,Ji-Xing Nan,Xue-Jun Jin,Qing-Gao Zhang
DOI: https://doi.org/10.3390/ijms23158494
IF: 5.6
2022-07-31
International Journal of Molecular Sciences
Abstract:Inflammatory bowel disease (IBD) is a chronic, relapsing disease that severely affects patients' quality of life. The exact cause of IBD is uncertain, but current studies suggest that abnormal activation of the immune system, genetic susceptibility, and altered intestinal flora due to mucosal barrier defects may play an essential role in the pathogenesis of IBD. Unfortunately, IBD is currently difficult to be wholly cured. Thus, more treatment options are needed for different patients. Stem cell therapy, mainly including hematopoietic stem cell therapy and mesenchymal stem cell therapy, has shown the potential to improve the clinical disease activity of patients when conventional treatments are not effective. Stem cell therapy, an emerging therapy for IBD, can alleviate mucosal inflammation through mechanisms such as immunomodulation and colonization repair. Clinical studies have confirmed the effectiveness of stem cell transplantation in refractory IBD and the ability to maintain long-term remission in some patients. However, stem cell therapy is still in the research stage, and its safety and long-term efficacy remain to be further evaluated. This article reviews the upcoming stem cell transplantation methods for clinical application and the results of ongoing clinical trials to provide ideas for the clinical use of stem cell transplantation as a potential treatment for IBD.
biochemistry & molecular biology,chemistry, multidisciplinary